October 1, 2018 07:38 AM EDT

Three years after selling Acerta to AstraZeneca in $7B deal, Dave Johnson is back at the helm of a biotech startup

John Carroll

Editor & Founder

Three years ago Dave Johnson steered Acerta to a $7 billion buyout deal with AstraZeneca, setting up a relatively quickly transition of acalabrutinib into the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Three years after selling Acerta to AstraZeneca in $7B deal, Dave Johnson is back at the helm of a biotech startup

John Carroll

Editor & Founder

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Three years af­ter sell­ing Ac­er­ta to As­traZeneca in $7B deal, Dave John­son is back at the helm of a biotech start­up

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Three years after selling Acerta to AstraZeneca in $7B deal, Dave Johnson is back at the helm of a biotech startup

Novartis to cut 139 jobs in NJ as part of commercial refocus

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Outlook's shares crash as wet AMD drug flunks Phase 3 test